Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers

Gynecologic Oncology

Volumn 106, Issue 3, 2007, Pages 614-621

  Kendrick, James E ^a   Estes, Jacob M ^a   Straughn Jr , J Michael ^a   Alvarez, Ronald D ^a   Buchsbaum, Donald J ^b  

^a University of Alabama   (United States)

^b The University of Alabama at Birmingham   (United States)

Author keywords

Breast; Cancer; Cervix; Endometrium; Ovary; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CD95 MONOCLONAL ANTIBODY; CISPLATIN; DOXORUBICIN; DR5 ANTIBODY; GEMCITABINE; HGS TR2J; INTERFERON; LEXATUMUMAB; LUTEOLIN; MAPATUMUMAB; MONOCLONAL ANTIBODY; PACLITAXEL; PLACEBO; PRO 1762; TOPOTECAN; TRA 8; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; BREAST CANCER; CANCER CELL CULTURE; CANCER GRADING; CANCER RADIOTHERAPY; CELL DEATH; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG ACTIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ENDOMETRIUM CANCER; GENETIC ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PEER REVIEW; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; UTERINE CERVIX BIOPSY; UTERINE CERVIX DYSPLASIA;

ANTIBODIES, MONOCLONAL; APOPTOSIS; BREAST NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 34548132882     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.05.035     Document Type: Review

References (84)

1. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 1 (2000) 57-70
2. Lee J.M., and Bernstein A. Apoptosis, cancer and the p53 tumour suppressor gene. Cancer Metastasis Rev. 14 2 (1995) 149-161
3. Orrenius S. Mitochondrial regulation of apoptotic cell death. Toxicol. Lett. 149 1-3 (2004) 19-23
4. Hill M.M., Adrain C., and Martin S.J. Portrait of a killer: the mitochondrial apoptosome emerges from the shadows. Mol. Interv. 3 1 (2003) 19-26
5. Takahashi A. Caspase: executioner and undertaker of apoptosis. Int. J. Hematol. 70 4 (1999) 226-232
6. Igney F.H., and Krammer P.H. Death and anti-death: tumour resistance to apoptosis. Nat. Rev., Cancer. 2 4 (2002) 277-288
7. Opferman J.T., and Korsmeyer S.J. Apoptosis in the development and maintenance of the immune system. Nat. Immunol. 4 5 (2003) 410-415
8. Walczak H., Bouchon A., Stahl H., and Krammer P.H. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. Cancer Res. 60 (2000) 3051-3057
9. Vousden K.H., and Lu X. Live or let die: the cell's response to p53. Nat. Rev., Cancer. 2 8 (2002) 594-604
10. Le Blanc H.N., and Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10 (2003) 66-75
11. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
12. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104 (1999) 155-162
13. Griffith T.S., and Lynch D.H. TRAIL: a molecule with multiple receptors and control mechanisms. Curr. Opin. Immunol. 10 5 (1998) 559-563
14. Barnhart B.C., Alappat E.C., and Peter M.E. The CD95 type I/type II model. Semin. Immunol. 15 3 (2003) 185-193
15. Micheau O., and Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114 2 (2003) 181-190
16. Rowinsky E.K. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J. Clin. Oncol. 23 (2005) 9394-9407
17. Varfolomeev E.E., and Ashkenazi A. Tumor necrosis factor: an apoptosis JuNKie?. Cell 116 4 (2004) 491-497
18. Armstrong J.S. Mitochondrial medicine: pharmacological targeting of mitochondria in disease. Br. J. Pharmacol. (2007) [Electronic publication ahead of print]
19. Pan G., Ni J., Wei Y.-F., Yu G.-l., Gentz R., and Dixit V.M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277 5327 (1997) 815-818
20. Pan G., O'Rourke K., Chinnaiyan A.M., Gentz R., Ebner R., Ni J., et al. The receptor for the cytotoxic ligand TRAIL. Science 276 (1997) 111-113
21. Sheridan J.P., Marsters S.A., Pitti R.M., Gurney A., Skubatch M., Baldwin D., et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277 5327 (1997) 818-821
22. Walczak H., Degli-Esposti M.A., Johnson R.S., Smolak P.J., Waugh J.Y., Boiani N., et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16 17 (1997) 5386-5397
23. Buchsbaum D.J., Zhou T., Grizzle W.E., Oliver P.G., Hammond C.J., Zhang S., et al. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin. Cancer Res. 9 (2003) 3731-3741
24. Ichikawa K., Liu W., Zhao L., Wang Z., Liu D., Ohtsuka T., et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 7 (2001) 954-960
25. Straughn Jr. J.M., Oliver P.G., Zhou T., Wang W., Alvarez R.D., Grizzle W.E., et al. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecol. Oncol. 101 (2006) 46-54
26. Kelley S.K., and Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr. Opin. Pharmacol. 4 (2004) 333-339
27. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., and Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. U. S. A. 72 9 (1975) 3666-3670
28. Hersh E.M., Metch B.S., Muggia F.M., Brown T.D., Whitehead R.P., Budd G.T., et al. Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: a summary of the Southwest Oncology Group experience. J. Immunother. 10 6 (1991) 426-431
29. Jones A.L., and Selby P. Tumour necrosis factor: clinical relevance. Cancer Surv. 8 4 (1989) 817-836
30. Ashkenazi A., and Dixit V.M. Death receptors: signaling and modulation. Science 281 5381 (1998) 1305-1308
31. Kelley S.K., Harris L.A., Xie D., Deforge L., Totpal K., Bussiere J., et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther. 299 1 (2001) 31-38
32. Lawrence D., Shahrokh Z., Marsters S., Achilles K., Shih D., Mounho B., et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 7 (2001) 383-385
33. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5 (1999) 157-163
34. Almasan A., and Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 14 (2003) 337-348
35. Cuello M., Ettenberg S.A., Nau M.M., and Lipkowitz S. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol. Oncol. 81 (2001) 380-390
36. Jin H., Yang R., Fong S., Totpal K., Lawrence D., Zheng Z., et al. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res. 64 (2004) 4900-4905
37. Komdeur R., Meijer C., Van Zweeden M., De Jong S., Wesseling J., Hoekstra H.J., et al. Doxorubicin potentiates TRAIL cytotoxicity and apoptosis and can overcome TRAIL-resistance in rhabdomyosarcoma cells. Int. J. Oncol. 25 (2004) 677-684
38. Lane D., Cartier A., L'Esperance S., Cote M., Rancourt C., and Piche A. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells. Gynecol. Oncol. 93 (2004) 594-604
39. Naka T., Sugamura K., Hylander B.L., Widmer M.B., Rustum Y.M., and Repasky E.A. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res. 62 (2002) 5800-5806
40. Ravi R., Jain A.J., Schulick R.D., Pham V., Prouser T.S., Allen H., et al. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res. 64 (2004) 9105-9114
41. Ray S., and Almasan A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res. 63 (2003) 4713-4723
42. Singh T.R., Shankar S., Chen X., Asim M., and Srivastava R.K. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res. 63 (2003) 5390-5400
43. Van Valen F., Fulda S., Schafer K.L., Truckenbrod B., Hotfilder M., Poremba C., et al. Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells. Int. J. Cancer 107 (2003) 929-940
44. Chinnaiyan A.M., Prasad U., Shankar S., Hamstra D.A., Shanaiah M., Chenevert T.L., et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl. Acad. Sci. U. S. A. 97 4 (2000) 1754-1759
45. Ashkenazi A., and Dixit V.M. Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol. 11 (1999) 255-260
46. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354 (2006) 567-578
47. Goldenberg M.M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin. Ther. 21 2 (1999) 309-318
48. Monk B.J., Choi D.C., Pugmire G., and Burger R.A. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol. Oncol. 96 3 (2005) 902-905
49. Dobson C.L., Edwards B., Main S., Minter R., Williams L., Salcedo T.W., et al. Generation of human therapeutic anti-TRAIL-R1 agonistic antibodies by phage display. Proc. Am. Assoc. Cancer Res. 43 (2002) 579
50. Griffith T.S., Rauch C.T., Smolak P.J., Waugh J.Y., Boiani N., Lynch D.H., et al. Functional analysis of TRAIL receptors using monoclonal antibodies. J. Immunol. 162 5 (1999) 2597-2605
51. Cohen R.B., Meropol N.J., Padavic K., Weiner L.M., Mita M., Patnaik A., et al. A phase I clinical trial of HGS-ETR1, an agonist monoclonal antibody to TRAIl-R1, in patients with advanced solid tumors. EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (2004), Geneva, Switzerland
52. Hotte S.J., Oza A.M., Le L.H., MacLean M., Iacobucci A., Corey A., et al. Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL). EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (2004), Geneva, Switzerland
53. Tolcher A.W., Mita M., Patnaik A., Rowinsky E.K., Corey A., Fleming M., et al. A phase I and pharmacokinetic study of HGS-ETR1 (TRM-1), a human monoclonal agonist-antibody to TRAIL-R1 in patients with advanced solid tumors. J. Clin. Oncol. 23 (2004) 210
54. Hotte S.J., Hirte H.W., Chen E.X., Le L.H., Corey A., Maclean M., et al. HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase I trial. J. Clin. Oncol. 23 (2005) 16
55. Patnaik A., Wakelee H., Mita M., Fitzgerald A., Hill M., Fox N., et al. HGS-ETR2-A fully human monoclonal antibody to TRAIL-R2: results of a phase I trial in patients with advanced solid tumors. J. Clin. Oncol. 24 (2006) 18s
56. Chow L.Q., Eckhardt S.G., Gustafson D.L., O'Bryant C., Hariharan S., Diab S., et al. HGS-ETR1, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and PK study. J. Clin. Oncol. 24 (2006) 18s
57. Mom C.H., Sleijfer S., Gietema J.A., Sneller V., Fox N.L., Lo L., et al. A phase 1 study of HGS-ETR1, a fully human agonistic monoclonal antibody to the TRAIL-R1, in combination with gemcitabine and cisplatin in subjects with advanced solid malignancies. Clin. Cancer Res. 11 (2005) 9117s
58. Sadarangani A., Kato S., Espinoza N., Lange S., Llados C., Espinosa M., et al. TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract. Apoptosis 12 1 (2007) 73-85
59. Ryu H.S., Chang K.H., Chang S.J., Kim M.S., Joo H.J., and Oh K.S. Expression of TRAIL (TNF-related apoptosis-inducing ligand) receptors in cervical cancer. Int. J. Gynecol. Cancer 10 (2000) 417-424
60. Horinaka M., Yoshida T., Shiraishi T., Nakata S., Wakada M., Nakanishi R., et al. The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells. Biochem. Biophys. Res. Commun. 333 3 (2005) 833-838
61. Hougardy B.M., Maduro J.H., van der Zee A.G., Willemse P.H., de Jong S., and de Vries E.G. Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: changing the apoptotic balance. Lancet Oncol. 6 8 (2005) 589-598
62. Reesink-Peters N., Hougardy B.M., van den Heuvel F.A., Ten Hoor K.A., Hollema H., Boezen H.M., et al. Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynecol. Oncol. 96 (2005) 705-713
63. Cheung T.H., Chung T.K., Lo K.W., Yu M.Y., Krajewski S., Reed J.C., et al. Apoptosis-related proteins in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix. Gynecol. Oncol. 86 (2002) 14-18
64. Jain D., Srinivasan R., Patel F.D., and Kumari Gupta S. Evaluation of p53 and Bcl-2 expression as prognostic markers in invasive cervical carcinoma stage IIb/III patients treated by radiotherapy. Gynecol. Oncol. 88 (2003) 22-28
65. Wootipoom V., Lekhyananda N., Phungrassami T., Boonyaphiphat P., and Thongsuksai P. Prognostic significance of Bax, Bcl-2, and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy. Gynecol. Oncol. 94 (2004) 636-642
66. Green M.M., Hutchison G.J., Valentine H.R., Fitzmaurice R.J., Davidson S.E., Hunter R.D., et al. Expression of the proapoptotic protein Bid is an adverse prognostic factor for radiotherapy outcome in carcinoma of the cervix. Br. J. Cancer 92 (2005) 449-458
67. Sultana H., Kigawa J., Kanamori Y., Itamochi H., Oishi T., Sato S., et al. Chemosensitivity and p53-Bax pathway-mediated apoptosis in patients with uterine cervical cancer. Ann. Oncol. 14 (2003) 214-219
68. Hougardy B.M., van der Zee A.G., van den Heuvel F.A., Timmer T., de Vries E.G., and de Jong S. Sensitivity to Fas-mediated apoptosis in high-risk HPV-positive human cervical cancer cells: relationship with Fas, caspase-8, and Bid. Gynecol. Oncol. 97 (2005) 353-364
69. Aguilar-Lemarroy A., Kirchhoff S., Whitaker N., Gariglio P., zur Hausen H., Krammer P.H., et al. Differential sensitivity of human papillomavirus type 16(+) and type 18(+) cervical carcinoma cells to CD95-mediated apoptosis. Int. J. Cancer 93 (2001) 823-831
70. Horinaka M., Yoshida T., Shiraishi T., Nakata S., Wakada M., Nakanishi R., et al. Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells. Oncogene 24 (2005) 7180-7189
71. Enfeng Z., Meiquing Z., Caiying F., Beifen S., Zhang Q., and Lijuan L. Effects of TNF alone or in combination with chemotherapeutic agents on human ovarian cancer in vitro and in nude mice. Chin. Med. J. (Engl.) 108 (1995) 571-575
72. Horak P., Pils D., Roessler M., Tomek S., Elandt K., Zeillinger R., et al. Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer. Gynecol. Oncol. 97 2 (2005) 514-518
73. Lancaster J.M., Sayer R., Blanchette C., Calingaert B., Whitaker R., Schildkraut J., et al. High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival. Clin. Cancer Res. 9 2 (2003) 762-766
74. Abedini M.R., Qiu Q., Yan X., and Tsang B.K. Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Oncogene 23 42 (2004) 6997-7004
75. Horak P., Pils D., Kaider A., Pinter A., Elandt K., Sax C., et al. Perturbation of the tumor necrosis factor-related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5. Clin. Cancer Res. 11 24 Pt. 1 (2005) 8585-8591
76. Fulda S., and Debatin K.M. IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 21 15 (2002) 2295-2308
77. Huang X., Lin T., Gu J., Zhang L., Roth J.A., Stephens L.C., et al. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft. Gene Ther. 9 20 (2002) 1379-1386
78. Williams J., Lucas P.C., Griffith K.A., Choi M., Fogoros S., Hu Y.Y., et al. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol. Oncol. 96 2 (2005) 287-295
79. Tomek S., Horak P., Pribill I., Haller G., Rossler M., Zielinski C.C., et al. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. Gynecol. Oncol. 94 (2004) 107-114
80. Arts H.J., de Jong S., Hollema H., ten Hoor K., van der Zee A.G., and Vries deE.G. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma. Gynecol. Oncol. 92 (2004) 794-800
81. Ohtsuka T., Buchsbaum D., Oliver P., Makhija S., Kimberly R., and Zhou T. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 22 (2003) 2034-2044
82. Vignati S., Codegoni A., Polato F., and Broggini M. Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs. Eur. J. Cancer 38 (2002) 177-183
83. Abdollahi T., Robertson N.M., Abdollahi A., and Litwack G. Inhibition of TRAIL-induced apoptosis by IL-8 is mediated by the p38-MAPK pathway in OVCAR3 cells. Apoptosis 10 6 (2005) 1383-1393
84. Cuello M., Ettenberg S.A., Clark A.S., Keane M.M., Posner R.H., Nau M.M., et al. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. (Suppl.) 61 (2001) 4892-4900